6-Bromo-2-oxo-N-[2-(piperidin-1-yl)ethyl]-2H-chromene-3-carboxamide

Catalog No.: 
ACPOOA143
CAS No.: 
81309-18-4
Molecular Formula: 
C17H19BrN2O3
Molecular Weight: 
379.25
6-Bromo-2-oxo-N-[2-(piperidin-1-yl)ethyl]-2H-chromene-3-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg90%$109.00InquiryInquiry
1g90%$323.00InquiryInquiry
5g90%$1599.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Bromo-2-oxo-N-[2-(piperidin-1-yl)ethyl]-2H-chromene-3-carboxamide
IUPAC Name6-bromo-2-oxo-N-(2-(piperidin-1-yl)ethyl)-2H-chromene-3-carboxamide
MDL No.MFCD05669714
Molecular FormulaC17H19BrN2O3
Molecular Weight379.25
SMILESO=C(C(C1=O)=CC2=C(O1)C=CC(Br)=C2)NCCN3CCCCC3
InChI KeyVKXQLBXMGCGRFL-UHFFFAOYSA-N
Synonym6-bromo-2-oxo-N-[2-(piperidin-1-yl)ethyl]-2H-chromene-3-carboxamide;2H-1-Benzopyran-3-carboxamide, 6-bromo-2-oxo-N-[2-(1-piperidinyl)ethyl]-
CAS No.81309-18-4

Synthetic Route by SureRoute

1. ACPOOA143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNMVP780 route compound structure diagram
    ACNMVP7802199-87-3In Stock
  4. Then
  5. ACPOOA143 route product structure diagram
    ACPOOA14381309-18-4
Inquiry

2. ACPOOA143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACOUML912 route compound structure diagram
    ACOUML9122199-90-8In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPOOA143 route product structure diagram
    ACPOOA14381309-18-4
Inquiry

3. ACPOOA143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPOOA143 route product structure diagram
    ACPOOA14381309-18-4
Inquiry

Comments (0)